Perivascular adipose tissue control of insulin-induced vasoreactivity in muscle is impaired in db/db mice

Rick I Meijer1, Wineke Bakker, Caro-Lynn A F Alta

  • 1Department of Internal Medicine, VU University Medical Center, Amsterdam, The Netherlands.

Diabetes
|October 11, 2012
PubMed

Insights

Perivascular adipose tissue (PVAT) controls muscle insulin sensitivity. In obesity, PVAT impairs insulin-induced vasodilation, but inhibiting JNK can restore this function via adiponectin and AMPK signaling.

Area of Science:

  • Physiology
  • Metabolic Research
  • Vascular Biology

Background:

  • Insulin sensitivity is crucial for muscle microvascular function.
  • The role of perivascular adipose tissue (PVAT) in insulin-induced vasoreactivity and its disruption in obesity remain unclear.
  • Understanding these mechanisms is vital for metabolic health.

Purpose of the Study:

  • To investigate if PVAT regulates insulin-induced vasodilation in muscle.
  • To elucidate the underlying mechanisms, including the role of adiponectin and AMPK signaling.
  • To determine how obesity-associated changes in PVAT affect insulin vasoreactivity.

Main Methods:

  • Studied insulin-induced vasoreactivity of resistance arteries with PVAT from lean (C57BL/6) and obese (db/db) mice.
  • Investigated the effects of blocking adiponectin and inhibiting Jun NH2-terminal kinase (JNK).
  • Utilized AMPKα2(+/+) and AMPKα2(-/-) mouse models to assess signaling pathways.

Main Results:

  • PVAT from lean mice facilitated insulin-induced vasodilation, while PVAT from obese mice abrogated it.
  • Adiponectin blockade abolished insulin vasodilation in lean PVAT; obese PVAT showed lower adiponectin secretion.
  • JNK inhibition in obese PVAT restored insulin vasodilation in an adiponectin-dependent manner, linked to AMPKα2 signaling.

Conclusions:

  • PVAT critically controls muscle microcirculation's insulin-induced vasoreactivity.
  • Obesity-associated PVAT impairs insulin vasodilation through reduced adiponectin and altered signaling.
  • Targeting JNK in PVAT offers a potential therapeutic strategy to restore insulin sensitivity in obesity.